306 related articles for article (PubMed ID: 17540032)
1. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.
Zagouri F; Sergentanis TN; Zografos GC
World J Surg Oncol; 2007 May; 5():57. PubMed ID: 17540032
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
Pinder SE; Ellis IO
Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
[TBL] [Abstract][Full Text] [Related]
3. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review.
Bonacho T; Rodrigues F; Liberal J
Biotech Histochem; 2020 Feb; 95(2):71-91. PubMed ID: 31502889
[TBL] [Abstract][Full Text] [Related]
5. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
[TBL] [Abstract][Full Text] [Related]
6. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
7. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
[TBL] [Abstract][Full Text] [Related]
8. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
9. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
10. [Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].
Piubello Q; Montemezzi S; D'Atri C
Pathologica; 2002 Dec; 94(6):299-305. PubMed ID: 12540993
[TBL] [Abstract][Full Text] [Related]
11. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma in situ (DCIS). A highly treatable breast cancer.
Mayo Clin Womens Healthsource; 2009 Oct; 13(10):1-2. PubMed ID: 19727033
[No Abstract] [Full Text] [Related]
13. Different proliferative patterns characterize different preinvasive breast lesions.
Viacava P; Naccarato AG; Bevilacqua G
J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
[TBL] [Abstract][Full Text] [Related]
14. [Does molecular biology play any role in ductal carcinoma in situ?].
Sakr RA
Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
[TBL] [Abstract][Full Text] [Related]
15. DCIS prognostic markers: a few new candidates emerge.
Nelson NJ
J Natl Cancer Inst; 2010 May; 102(9):588-90. PubMed ID: 20427428
[No Abstract] [Full Text] [Related]
16. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
17. Lobular neoplasia: morphology and management.
Jorns J; Sabel MS; Pang JC
Arch Pathol Lab Med; 2014 Oct; 138(10):1344-9. PubMed ID: 25268198
[TBL] [Abstract][Full Text] [Related]
18. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
[TBL] [Abstract][Full Text] [Related]
19. Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion.
Gobbi H; Jensen RA; Simpson JF; Olson SJ; Page DL
Hum Pathol; 2001 Aug; 32(8):785-90. PubMed ID: 11521220
[TBL] [Abstract][Full Text] [Related]
20. The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer.
Kavgaci H; Yildiz B; Fidan E; Reis A; Ozdemir F; Cobanoglu U; Can G
Bratisl Lek Listy; 2010; 111(9):493-7. PubMed ID: 21180263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
